MedTrace Logo

Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs

NCT06997185 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3000

Last updated 2025-05-30

No results posted yet for this study

Summary

This nationally representative randomized survey of US adults will evaluate the effect of using brief statements to communicate different sources of uncertainty about the benefits and harms of new cancer drugs on participants' decisions and understanding.

Conditions

Interventions

OTHER

Statement communicating uncertainty with a single arm trial

Because Zenova has not been compared to other treatments, it is unknown if Zenova is better, the same, or worse than other treatments for non-small cell lung cancer.

OTHER

Statement communicating uncertainty with limited study duration

Since patients given Zenova were followed for a short time, the longer-term benefits and harms of taking Zenova are unknown.

OTHER

Statement communicating uncertainty with a limited study population

Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.

OTHER

Statement communicating uncertainty with an unvalidated surrogate endpoint

Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live.

OTHER

Statement communicating uncertainty with treatment effect size

It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.

Sponsors & Collaborators

  • Harvard Medical School / Harvard Pilgrim Health Care Institute

    collaborator UNKNOWN

  • London School of Economics and Political Science

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-09
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06997185 on ClinicalTrials.gov